



## Enantioselective Synthesis of (*S*)-2-(Aminomethyl)butanedioic acid Using Chiral $\beta$ -Alanine $\alpha$ -Enolate Equivalents


Elena Arvanitis, Majid Motevalli and Peter B. Wyatt\*

Department of Chemistry, Queen Mary and Westfield College, University of London, Mile End Road, London E1 4NS, UK;  
E-mail p.b.wyatt@qmw.ac.uk

**Abstract:** (*S*)-2-(Aminomethyl)butanedioic acid (**6**) can be synthesised by stereoselective alkylation of the Na enolates of acyloxazolidinones **1a** and **1b** with methyl bromoacetate, then oxidation of the vinyl or dimethoxyphenyl substituent to a carboxyl group, followed by Curtius rearrangement and deprotection. The absolute configuration of **6** has been correlated with that of (*S*)-1-phenylethylamine by a combination of crystallographic and chemical means.  
Copyright © 1996 Elsevier Science Ltd

2-(Aminomethyl)butanedioic acid (**6**) is a homologue of aspartic acid and an isomer of glutamic acid, both of which are important neurotransmitters.<sup>1</sup> It has been shown that the neuroexcitatory effects upon the toad spinal cord follow the order D-Glu > ( $\pm$ )-**6** > D-Asp > L-Glu > L-Asp.<sup>2</sup> We now report the first asymmetric synthesis of **6**. Although there is considerable current interest in the stereoselective synthesis of  $\beta$ -amino acids,<sup>3</sup> there have been very few reports of enantioselective routes to  $\alpha$ -substituted,  $\beta$ -unsubstituted  $\beta$ -alanine derivatives. The approaches that have been used include the use of a perhydropyrimidine derivative as a chiral  $\beta$ -alanine  $\alpha$ -enolate equivalent,<sup>4</sup> the aminomethylation of a chiral enolate in an asymmetric Mannich reaction<sup>5</sup> and the Michael reactions of chiral  $\alpha$ -methylene- $\beta$ -alanine derivatives with carbon nucleophiles.<sup>6</sup> Here we describe a synthesis of (*S*)-**6** in which the 3-(pent-4-enoyl)- and 3-[3-(3,4-dimethoxyphenyl)propanoyl]-oxazolidinones **1a** and **1b** can be considered to act as new chiral  $\beta$ -alanine  $\alpha$ -enolate equivalents.

We have recently demonstrated that the acyloxazolidinones **1a** and **1b** bearing Evans' chiral auxiliary<sup>7</sup> are able to undergo diastereoselective cyanomethylation by BrCH<sub>2</sub>CN. Oxidation (RuCl<sub>3</sub>-NaIO<sub>4</sub>) of the vinyl and 3,4-dimethoxyphenyl substituents, to give carboxyl groups, can be performed with the chiral auxiliary in place.<sup>8</sup> In the present synthesis BrCH<sub>2</sub>CO<sub>2</sub>Me is used as the electrophile.<sup>9</sup> The major alkylation product **2b** is crystalline and was found to be easier to purify than the **2a**, which remained oily. Oxidation of either **2a** or **2b** gave the same carboxylic acid **3** which, upon treatment with (PhO)<sub>2</sub>P(O)N<sub>3</sub>/PhCH<sub>2</sub>OH/Et<sub>3</sub>N, yielded the *N*-benzyloxycarbonyl-protected amino acid derivative **4** via a Curtius rearrangement of the acyl azide.<sup>10</sup> Cleavage of the chiral auxiliary and hydrolysis of the methyl ester group in **4** were performed in a single operation: it was observed that the ester hydrolysis was the slower of these two reactions. Catalytic hydrogenolysis and recrystallisation from H<sub>2</sub>O-EtOH then afforded (*S*)-**6** as the monohydrate.



**Scheme 1.** Reagents and conditions: i,  $\text{NaN}(\text{SiMe}_3)_2$ , THF,  $-78^\circ\text{C}$ , 30 min, then  $\text{MeO}_2\text{CCH}_2\text{Br}$ , warm to  $-15^\circ\text{C}$  over 2h, then  $\text{NH}_4\text{Cl}$  (aq) (60% yield for **2a**, 53% for **2b**); ii,  $\text{RuCl}_3$ ,  $\text{NaIO}_4$ , MeCN,  $\text{CCl}_4$ ,  $\text{H}_2\text{O}$ , then *i*-PrOH (83% from **2a**, 75% from **2b**); iii,  $(\text{PhO})_2\text{P}(\text{O})\text{N}_3$ ,  $\text{Et}_3\text{N}$ ,  $\text{PhCH}_2\text{OH}$ ,  $\text{PhMe}$ , 2 h,  $20^\circ\text{C}$  then 2 h reflux (70%); iv,  $\text{LiOH}$ ,  $\text{H}_2\text{O}_2$ ,  $\text{H}_2\text{O}$ , THF,  $0^\circ\text{C}$ , 4 h (65%); v,  $\text{H}_2$ , Pd-C, AcOH, 3 h,  $20^\circ\text{C}$  (89%); vi,  $\text{CH}_2\text{N}_2$ , MeOH,  $20^\circ\text{C}$ , then  $\text{H}_2$ , Pd-C, MeOH, 3 h,  $20^\circ\text{C}$ , then  $\text{Et}_3\text{N}$ , MeOH, 1 d,  $20^\circ\text{C}$  (41% from **5**); vii, (*S*)-1-phenylethylamine,  $160^\circ\text{C}$ , 4 h then crystallisation from EtOAc (28%); viii, Na,  $\text{NH}_3$  (l), *t*-BuOH,  $-33^\circ\text{C}$ , 1 h, then  $\text{NH}_4\text{Cl}$  then  $\text{CH}_2\text{N}_2$ , MeOH (5% from **9**).


In order to estimate the enantiomeric excess of the products **5** and **6** and to verify that their absolute configurations were in accord with the accepted model for alkylation of acyloxazolidinones,<sup>7</sup> the dicarboxylic acid **5** was esterified with diazomethane and then subjected to hydrogenolysis in methanol to give the dimethyl ester of **6**. Cyclisation to the lactam **7** was found to be rather slow, but did occur when the diester of **6** was treated with excess  $\text{Et}_3\text{N}$  in MeOH at  $20^\circ\text{C}$ . The lactam **7** was purified by flash chromatography in EtOAc but was not recrystallised, so as to avoid disturbing the enantiomeric excess. The 600 MHz  $^1\text{H}$  NMR spectrum of **7** (15 mg) in  $\text{CDCl}_3$  (0.6 ml), in the presence of the chiral shift reagent tris[3-(trifluoromethylhydroxymethylene)-(+)-camphorato]europium (III) (20 mg), showed methyl ester signals at  $\delta$  3.97 and 3.92. These peaks, attributed respectively to the (*S*)- and (*R*)- enantiomers of the lactam **7**, were found to have integrals in the ratio  $> 97.5:2.5$ , corresponding to an enantiomeric excess for the lactam **7** of  $> 95\%$ .

Heating itaconic acid (**8**) with (*S*)-1-phenylethylamine gives a 1:1 mixture of diastereoisomeric pyrrolidonecarboxylic acids, which have previously been separated by conversion into the methyl esters.<sup>11,12</sup> We found that one of the carboxylic acids had a relatively low solubility in ethyl acetate and could be isolated by recrystallisation from this solvent. An X-ray crystal structure (Fig. 1) confirmed that the less soluble acid **9** had the (*S*)- configuration at C-4. Reductive cleavage of the *N*-( $\alpha$ -methylbenzyl) group, followed by

esterification with diazomethane, then gave a sample of (*S*)-7, [ $\alpha$ ]<sup>35</sup>D -19 (*c* 0.56 in CHCl<sub>3</sub>) {compare [ $\alpha$ ]<sup>30</sup>D -18 (*c* 1.1 in CHCl<sub>3</sub>) for (*S*)-7 prepared from 5}.

Thus we have further demonstrated the usefulness of the intermediates **2a** and **2b** in the synthesis of unusual amino acids of predictable absolute configuration.

We thank Mr P. D. Cook, Mr G. Coumbarides, Miss J. Isaacs, and Dr C. Z. Smith for recording spectra and Mr I. Mavrides for preparing a racemic sample of **6**. We are grateful to the University of London Central Research Fund for financial support and to the ULIRS for 600 MHz <sup>1</sup>H NMR spectroscopy.



**Fig. 1.** X-Ray crystal structure of **9**. Crystallographic data: <sup>13</sup> orthorhombic, space group *P*2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> with *a* = 6.584(1) Å, *b* = 8.258(1) Å, *c* = 22.310(2) Å, *U* = 1212.9(3) Å<sup>3</sup>; *Z* = 4; *D<sub>c</sub>* = 1.277 g cm<sup>-3</sup>; *T* = 293(2) K; λ = 0.71069 Å; μ (Mo-Kα) = 0.091 mm<sup>-1</sup>; 567 independent reflections. Structure solved by direct methods. H atoms of the CO<sub>2</sub>H, Me and Ph groups were placed in idealised positions using an atom-riding model. *R*<sub>1</sub> = 0.040, *wR*<sub>2</sub> = 0.088 for reflections with *I* > 2σ(*I*).

#### OTHER SELECTED DATA

**2a.** Pale yellow oil, chromatographed on silica gel in CH<sub>2</sub>Cl<sub>2</sub>-Et<sub>2</sub>O (49:1); <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): δ = 0.92 (d, 3 H, *J* 7 Hz), 2.18-2.33 (m, 1 H), 2.39-2.51 (m, 1 H), 2.53 (dd, 1 H, *J* 17, 5 Hz), 2.87 (dd, 1 H, *J* 17, 10 Hz), 3.64 (s, 3 H), 4.25-4.39 (m, 1 H), 4.76 (quintet, 1 H, *J* 7 Hz), 5.03-5.18 (m, 2 H), 5.65 (d, 1 H, *J* 7 Hz), 5.70-5.89 (m, 1 H), 7.30-7.47 (m, 5 H); *m/z* (EI) 331 (*M*<sup>+</sup>, 44%), 178 (100), (found: 331.1419. C<sub>18</sub>H<sub>21</sub>NO<sub>5</sub> requires 331.1420).

**2b.** White crystals, chromatographed on silica gel in CH<sub>2</sub>Cl<sub>2</sub>-Et<sub>2</sub>O (97:3), then recrystallised from Et<sub>2</sub>O-petrol, m.p. 98-100°C, [ $\alpha$ ]<sup>31</sup>D = +59 (*c* 0.2, CH<sub>2</sub>Cl<sub>2</sub>);  $\nu_{\max}$  (KBr)/cm<sup>-1</sup>: 1777, 1744, 1706; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): δ = 0.90 (d, 3 H, *J* 7 Hz), 2.46 (dd, 1 H, *J* 17, 5 Hz), 2.62 (dd, 1 H, *J* 14, 9 Hz), 2.89 (dd, 1 H, *J* 17, 10 Hz), 3.00 (dd, 1 H, *J* 14, 6 Hz), 3.61 (s, 3 H), 3.86 (s, 3 H), 3.90 (s, 3 H), 4.45-4.60 (m, 1 H), 4.65 (quintet, 1 H, *J* 7 Hz), 5.42 (d, 1 H, *J* 7 Hz), 6.75-6.83 (m, 2 H), 6.90 (d, 1 H, *J* 2 Hz), 7.26-7.46 (m, 5 H); *m/z* (EI) 441 (*M*<sup>+</sup>, 100%), (found: 441.1787. C<sub>24</sub>H<sub>27</sub>NO<sub>7</sub> requires 441.1788).

**3.** Colourless oil,  $\nu_{\max}$  (film)/cm<sup>-1</sup>: 1780, 1738, 1698; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): δ = 0.90 (d, 3 H, *J* 7 Hz), 2.56-2.96 (m, 4 H), 3.68 (s, 3 H), 4.41-4.53 (m, 1 H), 4.79 (quintet, 1 H, *J* 7 Hz), 5.71 (d, 1 H, *J* 7.5 Hz), 7.27-7.47 (m, 5 H); *m/z* (EI) 349 (*M*<sup>+</sup>, 48%), 107 (100), (found: 349.1155. C<sub>17</sub>H<sub>19</sub>NO<sub>7</sub> requires 349.1162).

4. Foam, chromatographed on silica gel in petrol-EtOAc,  $\nu_{\max}$  (KBr)/ $\text{cm}^{-1}$ : 3375, 1780, 1700;  $^1\text{H}$  NMR (250 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 0.88 (d, 3 H,  $J$  7 Hz), 2.58 (dd, 1 H,  $J$  16, 6 Hz), 2.89 (dd, 1 H,  $J$  17, 9 Hz), 3.43-3.52 (m, 2 H), 3.64 (s, 3 H), 4.29-4.39 (m, 1 H), 4.65 (quintet, 1 H,  $J$  7 Hz), 5.05-5.17 (m, 3 H), 5.60 (d, 1 H,  $J$  7 Hz), 7.27-7.45 (m, 10 H);  $m/z$ : (EI) 454 ( $M^+$ , 64%), 91 (100), (found: 454.1746.  $\text{C}_{24}\text{H}_{26}\text{N}_2\text{O}_7$  requires 454.1740).

5. White crystals (from EtOAc-petrol), m.p. 115°C,  $[\alpha]_{\text{D}}^{31} = +9.0$  ( $c$  0.5, acetone) (Found: C, 55.5; H, 5.4; N, 4.9.  $\text{C}_{13}\text{H}_{15}\text{NO}_6$  requires C, 55.5; H, 5.4; N, 5.0%);  $^1\text{H}$  NMR (250 MHz, acetone- $d_6$ ):  $\delta$  = 2.58 (dd, 1 H,  $J$  17.5, 5 Hz), 2.72 (dd, 1 H,  $J$  17.5, 7.5 Hz), 2.99-3.10 (m, 1 H), 3.36-3.62 (m, 2 H), 5.08 (s, 2 H), 6.39-6.52 (broad s), 7.23-7.44 (m, 5 H);  $m/z$  (EI) 281 ( $M^+$ , 14%), 91 (100), (found: 281.0889.  $\text{C}_{13}\text{H}_{15}\text{NO}_6$  requires 281.0899).

6.  $\text{H}_2\text{O}$ . White crystals (from  $\text{H}_2\text{O}$ -EtOH), m.p. 161°C,  $[\alpha]_{\text{D}}^{29} +7.3$  ( $c$  1.0, AcOH),  $[\alpha]_{\text{D}}^{30} +1.6$  ( $c$  0.7,  $\text{H}_2\text{O}$ ). (Found: C, 36.1; H, 6.6; N, 8.2.  $\text{C}_5\text{H}_9\text{NO}_4 \cdot \text{H}_2\text{O}$  requires C, 36.4; H, 6.7; N, 8.5%);  $^1\text{H}$  NMR (250 MHz,  $\text{D}_2\text{O}$ ):  $\delta$  = 2.57 (dd, 1 H,  $J$  17.5, 7.5 Hz), 2.72 (dd, 1 H,  $J$  17.5, 6 Hz), 2.88-2.99 (m, 1 H), 3.15 (dd, 1 H,  $J$  13, 4.5 Hz), 3.22 (dd, 1 H,  $J$  13, 9 Hz).

7. White crystals, chromatographed on silica gel in EtOAc, m.p. 78-80°C.  $^1\text{H}$  NMR (250 MHz,  $\text{CDCl}_3$ )  $\delta$  = 2.55 (dd, 1 H,  $J$  17.5, 10 Hz), 2.67 (dd, 1 H,  $J$  17.5, 7.5 Hz), 3.28-3.45 (m, 1 H), 3.62 (d', 2 H,  $J$  7.5 Hz), 3.74 (s, 3 H).

9. White crystals (from EtOAc), m.p. 199-202°C (lit.<sup>12</sup> for *ent*-9, 202-204°C),  $[\alpha]_{\text{D}}^{30} -100$  ( $c$  1.1, MeOH) [lit.<sup>12</sup> for *ent*-9, +102 (MeOH)].

#### REFERENCES AND NOTES

- McGeer, P. L. and McGeer, E. G. "Basic Neurochemistry: Molecular, Cellular and Medical Aspects", 4th Ed., Edited by Siegel, G. J.; Agranoff, B.; Albers, R. W and Molinoff, P., Raven Press Ltd., New York, 1989.
- Curtis, D. R.; Phillis, J. W.; Watkins, J. C. *Brit. J. Pharmacol.* **1961**, *16*, 262.
- For a review, see Cole, D. C. *Tetrahedron* **1994**, *50*, 9517.
- Juaristi, E.; Quintana, D. *Tetrahedron: Asymmetry* **1992**, *3*, 723.
- D'Souza, A. A.; Motevalli, M.; Robinson, A. J.; Wyatt, P. B. *J. Chem. Soc., Perkin Trans. 1* **1995**, *1*.
- Barnish, I. T.; Corless, M.; Dunn, P. J.; Ellis, D.; Finn, P. W., Hardstone, J. D., James, K. *Tetrahedron Lett.* **1993**, *34*, 1323.
- Evans, D. A.; Ennis, M. D.; Mathre, D. J. *J. Am. Chem. Soc.* **1982**, *104*, 1737.
- Azam, S.; D'Souza, A. A.; Wyatt, P. B. *J. Chem. Soc., Perkin Trans. 1* **1996**, 621.
- For previous examples of the use of haloesters to alkylate acyloxazolidinones, see Fadel, A.; Salaün, J. *Tetrahedron Lett.* **1988**, *29*, 6257.
- Shioiri, T.; Ninomiya, K.; Yamada, S. *J. Am. Chem. Soc.* **1972**, *94*, 6203.
- Nielsen, L.; Brehm, L.; Krosgaard-Larsen, P. *J. Med. Chem.* **1990**, *33*, 71.
- Culbertson, T. P.; Domagala, J. M.; Nichols, J. B.; Priebe, S.; Skeece, R. W. *J. Med. Chem.* **1987**, *30*, 1711.
- For crystallographic procedures, see Abrahams, I.; Motevalli, M.; Robinson, A. J.; Wyatt, P. B. *Tetrahedron*, **1994**, *50*, 12755. The authors have deposited atomic co-ordinates for the structure with the Cambridge Crystallographic Data Centre, University Chemical Laboratory, Lensfield Road, Cambridge CB2 1EW, UK.

(Received in UK 15 April 1996; accepted 26 April 1996)